Atlas Trials

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Clinical trial NCT06463548 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06463548
Sponsor
Yunpeng Liu
Status
NOT_YET_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Biliary Tract Carcinoma
Start date
2024-07-01
Primary completion
2025-12-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.